Navigation Links
Isis Highlights Robust Drug Portfolio for Diabetes and Obesity at ADA Conference
Date:6/10/2008

T1. In addition to being Isis' first antisense drug for a kidney target, ISIS 388626 is also unique due to its 12 nucleotide length rather than the more typical 18 - 21 nucleotide sequences that comprise Isis' other drugs. This attribute simplifies manufacturing and has the potential to substantially reduce related expenses. The short sequence may also contribute to ISIS 388626's unusually high potency; it is among the most potent antisense drugs that Isis has evaluated in preclinical models.

ABOUT ISIS PHARMACEUTICALS, INC.

Isis is exploiting its expertise in RNA to discover and develop novel drugs for its product pipeline and for its partners. The Company has successfully commercialized the world's first antisense drug and has 18 drugs in development. Isis' drug development programs are focused on treating cardiovascular and metabolic diseases. Isis' partners are developing antisense drugs invented by Isis to treat a wide variety of diseases. Ibis Biosciences, Inc., Isis' majority-owned subsidiary, is developing and commercializing the Ibis T5000(TM) Biosensor System, a revolutionary system to identify infectious organisms. Isis is a joint owner of Regulus Therapeutics LLC, a joint venture focused on the discovery, development and commercialization of microRNA therapeutics. As an innovator in RNA-based drug discovery and development, Isis is the owner or exclusive licensee of over 1,500 issued patents worldwide. Additional information about Isis is available at http://www.isispharm.com.

This press release includes forward-looking statements regarding the therapeutic and commercial potential of Isis' technologies and products in development for the treatment of metabolic diseases. Any statement describing Isis' goals, expectations, financial or other projections, intentions or beliefs is a forward-looking statement and should be considered an at-risk statement, including those statements that
'/>"/>

SOURCE Isis Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Uroplasty Highlights Clinical Results From a Study of the Urgent(R) PC Neuromodulation System
2. Memory Pharmaceuticals Highlights Progress with Key Programs at its R&D Day
3. Schering-Plough Highlights PEGINTRON(TM) and Boceprevir Hepatitis C Data Presentations at Digestive Disease Week (DDW) Annual Meeting
4. Schering-Plough Highlights PEGINTRON(TM) and Boceprevir Data Presentations at European Association for the Study of the Liver (EASL) Annual Meeting
5. Genta Incorporated Announces Fourth Quarter and Year End 2007 Financial Results and Corporate Highlights
6. Sarasotas Roskamp Institute Highlights Positive Japanese Data that Validates its Ongoing Alzheimers Disease Research
7. Research Highlights Potential Benefits of Telemedicine in Treating Eye Disease
8. Synvista Therapeutics Highlights New Data Demonstrating the Clinical Benefit of Vitamin E Therapy in Patients Identified on the Basis of Haptoglobin Phenotype Testing
9. Schering-Plough Highlights PEGINTRON(TM) Clinical Data Presentations at the American Association for the Study of Liver Diseases (AASLD) 2007 Annual Meeting
10. Genaera Corporation Provides Highlights of Positive Phase 1 Trodusquemine (MSI-1436) Data from the North American Association for the Study of Obesity Annual Meeting
11. President Clinton Highlights MWW Group at the 2007 Clinton Global Initiative for its Stop Neglected Tropical Disease Campaign

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/25/2009)...v. 25 ERT (Nasdaq: ERES...the Company,s President and CEO, and Keith Schneck...are scheduled to present at the 21st Annual Piper ...ecember 1, 2009 in New York City, New York. ,, ...visiting the Company,s corporate website at http:...
(Date:11/25/2009)...Nov. 25 Remedium Techno...like foam that stops severe bleeding, won first pr...a category of the Global Security Challenge 2009, ...rom more than 100 entries from around the world, R...Security Summit conference held at the London Scho...
(Date:11/25/2009)...25 Reportlinker.com announces that...catalogue: ,, Mammography Equipment - A Globa...ker.com/p0164330/Mammography-Equipment---A-Global-... breast cancer in industrialized as well as develo...wth in the mammography market. Globally, escalatin...
Breaking Medicine Technology:ERT to Present at the 21st Annual Piper Jaffray Health Care Conference on December 1, 2009 2Remedium Technologies Wins Most Promising Security Idea at Global Security Challenge 2009 with Blood-Clotting Foam 2Remedium Technologies Wins Most Promising Security Idea at Global Security Challenge 2009 with Blood-Clotting Foam 3Reportlinker Adds Mammography Equipment - A Global Market Perspective 2Reportlinker Adds Mammography Equipment - A Global Market Perspective 3Reportlinker Adds Mammography Equipment - A Global Market Perspective 4Reportlinker Adds Mammography Equipment - A Global Market Perspective 5Reportlinker Adds Mammography Equipment - A Global Market Perspective 6Reportlinker Adds Mammography Equipment - A Global Market Perspective 7Reportlinker Adds Mammography Equipment - A Global Market Perspective 8Cyberonics to Present at 21st Annual Piper Jaffray Health Care Conference 6430 1Cyberonics to Present at 21st Annual Piper Jaffray Health Care Conference 6430 2Biologists discover bacterial defense mechanism against aggressive oxygen 10837 1Biologists discover bacterial defense mechanism against aggressive oxygen 10837 2Carvedilol shown to have unique characteristics among beta blockers 10832 1Carvedilol shown to have unique characteristics among beta blockers 10832 2
...Conference Call Scheduled for 10:00 a.m. today, Th...uxilium,Pharmaceuticals, Inc. (Nasdaq: AUXL ) tod...ce from the U.S. Food and Drug Administration ("FD...AFLEX (clostridial collagenase,for injection), for...upuytren,s contracture. The Company will hold a co...
...Company on Target to File Supplemental New Drug Ap... Quarter, FRAZER, Pa., Aug. 16 Cephalon, Inc...from a 12-week, Phase 3 clinical,trial of FENTORA(...h,breakthrough pain associated with a broad range ...chieved statistical significance on the primary,en...
Other Medicine Technology:Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM) 2Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM) 3Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM) 4Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM) 5Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM) 6Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain 2Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain 3Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain 4Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain 5
(Date:11/27/2009)...INE, France, Nov. 27 Team Garmin-S... team dedicated to ethical sporting and developing...ed today that it will become Team Garmin-Transitio...ew sponsor of the team. Transitions Optical is the... offering the most advanced photochromic technolog...
(Date:11/27/2009)...-emission vehicles may reduce future disease burde...HealthDay News) -- Encouraging city dwellers to wa...uch greater public health benefits than increased ...ve found. , The study compared the projected he...nsport scenarios for London, England, and Delhi, I...
(Date:11/27/2009)...yant Health™ announced today that Spectrum H...aumaCad Enterprise orthopedic templating solution ... (PRWEB) November 27, 2009 -- ... Health (Grand Rapids, Michigan) has licensed its ...n and its TraumaCad Extend workflow solution, to a...
(Date:11/27/2009)...ree new interactive anatomy education apps from Mo...d health sciences learning opportunities for iPhon..., NC (Vocus) November 27, 2009 -- Modality, Inc. ...vision of Wolters Kluwer Health, today announced t...s on the App Store. Clemente’s Anatomy, Rohe...
(Date:11/26/2009)...number of Americans living with diabetes will near... 44.1 million in 2034. Over the same period, spend...13 billion to $336 billion, even with no increase ... the University of Chicago report in the December ...with diabetes covered by Medicare will rise from 8...
Breaking Medicine News(10 mins):Health News:Team Garmin-Slipstream Officially Re-named Team Garmin-Transitions With Addition of Transitions Optical as New Sponsor 2Health News:Team Garmin-Slipstream Officially Re-named Team Garmin-Transitions With Addition of Transitions Optical as New Sponsor 3Health News:More Foot Power, Less Car Pollution Best for Health 2Health News:Voyant Health Announces: Spectrum Health Licenses TraumaCad Enterprise and TraumaCad Extend 2Health News:Voyant Health Announces: Spectrum Health Licenses TraumaCad Enterprise and TraumaCad Extend 3Health News:Clemente's Anatomy, Rohen's Photographic Anatomy, and Moore's Clinical Anatomy Customizable Apps Now Available on App Store 2Health News:Clemente's Anatomy, Rohen's Photographic Anatomy, and Moore's Clinical Anatomy Customizable Apps Now Available on App Store 3Health News:Clemente's Anatomy, Rohen's Photographic Anatomy, and Moore's Clinical Anatomy Customizable Apps Now Available on App Store 4Health News:Clemente's Anatomy, Rohen's Photographic Anatomy, and Moore's Clinical Anatomy Customizable Apps Now Available on App Store 5Health News:Diabetes cases to double and costs to triple by 2034 2Health News:Diabetes cases to double and costs to triple by 2034 3
...dited by the Society of Chest Pain Centers (SCPC) ...ack core measures established by Centers for Medic...-accredited hospitals, according to a national stu... the Emory University School of Medicine, are repo...
... -- Many coaches inspire better performance by pre...re using pressure to improve the performance of th...ming problem, the researchers have found that addi...t Daniel Lopez-Ferrer, a post-doctoral researcher ...
... Cross country ride raised more than a hal...ams. , Baltimore, MD (Voc...ice program of the Foundation of the American Acad...olis as they conclude their transcontinental bike ...
...e soon on legislation that would cut $268 million,...HINGTON, July 9 Seniors across Minnesota,are spea...antage program in,legislation being considered in ...reas where Medicare private,fee-for-service plans ...
...y 9 Zeus Scientific, Inc. today,announced its int...ethicillin-resistant Staphylococcus aureus (MRSA)....nology utilizing the enrichment and nucleic acid,a... to identify carriers of this,pathogen within two ...
...July 9, 2008)Dr. Lee Kern, program coordinator and...ty,s College of Education in Bethlehem, Pa., will ...hing the National Research and Development Center ...t of Education to create the centera collaboration...
Other Medicine News:Health News:Chest pain center accreditation linked with better outcomes in heart attack patients 2Health News:Pressured proteins: A little pressure in proteomics squeezes 4-hour step into a minute 2Health News:Pressured proteins: A little pressure in proteomics squeezes 4-hour step into a minute 3Health News:National Non-Profit, EyeCare America, and the Maryland Society of Eye Physicians & Surgeons Host Finish Line Celebration for “EyeRide for Sight” Cyclists 2Health News:National Non-Profit, EyeCare America, and the Maryland Society of Eye Physicians & Surgeons Host Finish Line Celebration for “EyeRide for Sight” Cyclists 3Health News:National Non-Profit, EyeCare America, and the Maryland Society of Eye Physicians & Surgeons Host Finish Line Celebration for “EyeRide for Sight” Cyclists 4Health News:Minnesota Seniors Speak Out Against Medicare Advantage Cuts 2Health News:Lehigh to lead $9.6M national research center for serious behavior disorders 2Health News:Lehigh to lead $9.6M national research center for serious behavior disorders 3
Atraumatic Grasping Forceps (Fallopian), dual-incision
Optima III 45 Noninsulated Strong Forceps, with ratchet
Snap-In Snap-Out®-II Angulated Dissecting Forceps
Snap-In Snap-Out®-II Micro Dolphin Dissecting Forceps Insert
Medicine Products: